Abaloparatide fails to get EMA approval for use in osteoporosis
The European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP), has rejected the marketing application for abaloparatide subcutaneous injection for postmenopausal women with osteoporosis at increased risk for fracture. The drug has been approved by US FDA for the same indication.
To continue reading this article
Continue reading your article with a eMediNexus account.